

## COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

## RECENT NEWS

### **Propanc Biopharma, Inc. Secures up to \$100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline**

Nov 10 2025, 8:45 AM EST

### **Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)**

Nov 4 2025, 7:00 AM EST

### **Propanc Biopharma Announces Strategic Financing Agreement of up to \$100 Million with Hexstone Capital**

Oct 15 2025, 8:45 AM EDT

## STOCK OVERVIEW

|               |                     |
|---------------|---------------------|
| Symbol        | PPCB                |
| Exchange      | Nasdaq              |
| Market Cap    | 10.01m              |
| Last Price    | \$0.782             |
| 52-Week Range | \$0.7671 - \$145.46 |

11/13/2025 09:00 PM EST

## INVESTOR RELATIONS

Propanc Biopharma, Inc.  
T: +61-03-9882-6723  
[irteam@propanc.com](mailto:irteam@propanc.com)

## MANAGEMENT TEAM

**James Nathanielsz**  
CEO and Executive Chairman

**Dr. Julian Kenyon, M.D.**  
Chief Scientific Officer

**Professor Klaus Kutz, M.D.**  
Chief Medical Officer

**Jeannine Zimmerman**  
Chief Financial Officer

## PROPANC BIOPHARMA, INC.

302/6 Butler Street  
Camberwell, VIC 3124  
AU

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.